Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
12.89
-0.07 (-0.54%)
At close: Apr 28, 2026, 4:00 PM EDT
12.89
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:33 PM EDT
Entrada Therapeutics Employees
Entrada Therapeutics had 152 employees as of December 31, 2025. The number of employees decreased by 31 or -16.94% compared to the previous year.
Employees
152
Change (1Y)
-31
Growth (1Y)
-16.94%
Revenue / Employee
$167,243
Profits / Employee
-$945,724
Market Cap
464.04M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 152 | -31 | -16.94% |
| Dec 31, 2024 | 183 | 24 | 15.09% |
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Dec 31, 2021 | 114 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Ginkgo Bioworks Holdings | 485 |
| REGENXBIO | 371 |
| Aura Biosciences | 113 |
| Prelude Therapeutics | 79 |
| Assembly Biosciences | 73 |
| Larimar Therapeutics | 71 |
| Armata Pharmaceuticals | 60 |
TRDA News
- 2 months ago - Entrada Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study - GlobeNewsWire
- 2 months ago - Entrada Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts
- 2 months ago - Entrada Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Entrada Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference - Transcripts
- 3 months ago - Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - GlobeNewsWire